{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T17:03:18Z","timestamp":1792342998863,"version":"4.4.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","aaojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ophtha.2024.08.023","type":"journal-article","created":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T04:10:04Z","timestamp":1724472604000},"page":"271-279","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Comparative Effects of Glucagon-like Peptide 1 Receptor Agonists and Metformin on Glaucoma Risk in Patients with Type 2 Diabetes"],"prefix":"10.1016","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2830-9832","authenticated-orcid":false,"given":"Jawad","family":"Muayad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2136-4650","authenticated-orcid":false,"given":"Asad","family":"Loya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3436-2651","authenticated-orcid":false,"given":"Zain S.","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9735-7089","authenticated-orcid":false,"given":"Muhammad Z.","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer F.","family":"Alsoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0916-0911","authenticated-orcid":false,"given":"Ticiana","family":"De Francesco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5600-7242","authenticated-orcid":false,"given":"Iqbal Ike K.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ophtha.2024.08.023_bib1","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","article-title":"Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis","volume":"121","author":"Tham","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2024.08.023_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2023.101223","article-title":"Advances in understanding glaucoma pathogenesis: a multifaceted molecular approach for clinician scientists","volume":"94","author":"Ekici","year":"2023","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.ophtha.2024.08.023_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11892-021-01404-5","article-title":"Association between diabetes, diabetic retinopathy, and glaucoma","volume":"21","author":"Li","year":"2021","journal-title":"Curr Diab Rep"},{"issue":"2","key":"10.1016\/j.ophtha.2024.08.023_bib4","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ophtha.2007.04.049","article-title":"Type 2 diabetes mellitus and the risk of open-angle glaucoma: the Los Angeles Latino Eye Study","volume":"115","author":"Chopra","year":"2008","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ophtha.2024.08.023_bib5","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2014.07.051","article-title":"Diabetes, fasting glucose, and the risk of glaucoma: a meta-analysis","volume":"122","author":"Zhao","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2024.08.023_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11892-016-0815-6","article-title":"Presence and risk factors for glaucoma in patients with diabetes","volume":"16","author":"Song","year":"2016","journal-title":"Curr Diab Rep"},{"issue":"2","key":"10.1016\/j.ophtha.2024.08.023_bib7","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1177\/2040622315620180","article-title":"The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity","volume":"7","author":"Crane","year":"2016","journal-title":"Ther Adv Chronic Dis"},{"issue":"01","key":"10.1016\/j.ophtha.2024.08.023_bib8","article-title":"Monitoring report: GLP-1 RA prescribing trends-March 2024 Data, medRxiv","volume":"2024","author":"Gratzl","year":"2024","journal-title":"Preprint"},{"issue":"7","key":"10.1016\/j.ophtha.2024.08.023_bib9","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.ekir.2024.04.028","article-title":"Effects of once-weekly semaglutide on kidney disease outcomes by KDIGO risk category in the SUSTAIN 6 trial","volume":"9","author":"Tuttle","year":"2024","journal-title":"Kidney Int Rep"},{"issue":"10","key":"10.1016\/j.ophtha.2024.08.023_bib10","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.ophtha.2024.08.023_bib11","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/bph.15683","article-title":"The role of glia in the physiology and pharmacology of glucagon-like peptide-1: implications for obesity, diabetes, neurodegeneration and glaucoma","volume":"179","author":"Cui","year":"2022","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ophtha.2024.08.023_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2023.1156829","article-title":"Topical and systemic GLP-1R agonist administration both rescue retinal ganglion cells in hypertensive glaucoma","volume":"17","author":"Lawrence","year":"2023","journal-title":"Front Cell Neurosci"},{"issue":"7","key":"10.1016\/j.ophtha.2024.08.023_bib13","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.ophtha.2024.01.016","article-title":"Association of primary open-angle glaucoma with diabetic retinopathy among patients with type 1 and type 2 diabetes: a large global database study","volume":"131","author":"Chauhan","year":"2024","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.ophtha.2024.08.023_bib14","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaophthalmol.2023.4716","article-title":"Risk of stroke, myocardial infarction, and death after retinal artery occlusion","volume":"141","author":"Wai","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.08.023_bib15","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ajo.2024.02.023","article-title":"Association of ocular manifestations of Marfan syndrome with cardiovascular complications","volume":"264","author":"Tran","year":"2024","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.08.023_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.970925","article-title":"The neuroprotective effects of glucagon-like peptide 1 in Alzheimer\u2019s and Parkinson\u2019s disease: an in-depth review","volume":"16","author":"Reich","year":"2022","journal-title":"Front Neurosci"},{"issue":"6","key":"10.1016\/j.ophtha.2024.08.023_bib17","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1080\/02699052.2019.1587000","article-title":"GLP-1\u2019s role in neuroprotection: a systematic review","volume":"33","author":"Erbil","year":"2019","journal-title":"Brain Injury"},{"issue":"20","key":"10.1016\/j.ophtha.2024.08.023_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232012428","article-title":"Anti-inflammatory effects of GLP-1R activation in the retina","volume":"23","author":"Puddu","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.ophtha.2024.08.023_bib19","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1167\/iovs.15-19006","article-title":"Protective effect of a GLP-1 analog on ischemia-reperfusion induced blood\u2013retinal barrier breakdown and inflammation","volume":"57","author":"Gon\u00e7alves","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2024.08.023_bib20","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ajo.2024.08.030","article-title":"Association Between Glucagon-Like Peptide-1 Receptor Agonists Exposure and Intraocular Pressure Change: GLP-1 Receptor Agonists and Intraocular Pressure Change","volume":"269","author":"Hallaj","year":"2024","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.ophtha.2024.08.023_bib21","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/brain\/awad003","article-title":"The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial","volume":"146","author":"Mitchell","year":"2023","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.ophtha.2024.08.023_bib22","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/aps.2011.149","article-title":"Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells","volume":"33","author":"Ding","year":"2012","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.ophtha.2024.08.023_bib23","article-title":"Glucagon-like peptide-1 receptor agonists: new strategies and therapeutic targets to treat atherosclerotic cardiovascular disease","volume":"15","author":"Wang","year":"2024","journal-title":"Front Pharmacol"},{"issue":"Suppl 2","key":"10.1016\/j.ophtha.2024.08.023_bib24","article-title":"GLP1-RA versus metformin as first-line therapy for achieving glycemic control and risk-factor management-a one-year nationwide cohort study","volume":"44","author":"Soerensen","year":"2023","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.ophtha.2024.08.023_bib25","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.2337\/dc16-2368","article-title":"Is it time to change the type 2 diabetes treatment paradigm? Yes! GLP-1 RAs should replace metformin in the type 2 diabetes algorithm","volume":"40","author":"Abdul-Ghani","year":"2017","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.ophtha.2024.08.023_bib26","doi-asserted-by":"crossref","first-page":"886","DOI":"10.3357\/AMHP.5769.2021","article-title":"The correlation between body weight and intraocular pressure","volume":"92","author":"Khan","year":"2021","journal-title":"Aerospace Med Hum Perform"},{"issue":"5","key":"10.1016\/j.ophtha.2024.08.023_bib27","doi-asserted-by":"crossref","first-page":"e509","DOI":"10.1097\/IJG.0000000000000374","article-title":"Relationship between body mass index and intraocular pressure in men and women: a population-based study","volume":"25","author":"Cohen","year":"2016","journal-title":"J\u00a0Glaucoma"},{"issue":"5","key":"10.1016\/j.ophtha.2024.08.023_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0285759","article-title":"The effect of body mass index reduction on intraocular pressure in a large prospective cohort of apparently healthy individuals in Israel","volume":"18","author":"Coster","year":"2023","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.ophtha.2024.08.023_bib29","first-page":"5","article-title":"Wegovy (semaglutide): a new weight loss drug for chronic weight management","volume":"70","author":"Singh","year":"2022","journal-title":"J\u00a0Invest Med"},{"issue":"1","key":"10.1016\/j.ophtha.2024.08.023_bib31","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2337\/cd21-0043","article-title":"Recommendations for practical use of metformin, a central pharmacological therapy in type 2 diabetes","volume":"40","author":"Vieira","year":"2022","journal-title":"Clin Diabetes"},{"issue":"3","key":"10.1016\/j.ophtha.2024.08.023_bib32","doi-asserted-by":"crossref","first-page":"218","DOI":"10.7326\/0003-4819-156-3-201202070-00011","article-title":"Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians","volume":"156","author":"Qaseem","year":"2012","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.ophtha.2024.08.023_bib33","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/IJG.0000000000002387","article-title":"Metformin in glaucoma treatment","volume":"33","author":"Daka","year":"2024","journal-title":"J\u00a0Glaucoma"},{"issue":"8","key":"10.1016\/j.ophtha.2024.08.023_bib34","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1001\/jamaophthalmol.2015.1440","article-title":"Association of geroprotective effects of metformin and risk of open-angle glaucoma in persons with diabetes mellitus","volume":"133","author":"Lin","year":"2015","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"10.1016\/j.ophtha.2024.08.023_bib35","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s10792-024-02945-w","article-title":"Association between metformin use and the risk of developing open-angle glaucoma among patients with diabetes: a retrospective cohort study and meta-analysis","volume":"44","author":"Kim","year":"2024","journal-title":"Int Ophthalmol"},{"issue":"2","key":"10.1016\/j.ophtha.2024.08.023_bib36","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1136\/bjophthalmol-2021-319232","article-title":"Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma","volume":"107","author":"Sterling","year":"2023","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"10.1016\/j.ophtha.2024.08.023_bib37","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.ophtha.2024.03.004","article-title":"Association between glucagon-like peptide-1 receptor agonists and the risk of glaucoma in individuals with type 2 diabetes","volume":"131","author":"Niazi","year":"2024","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.ophtha.2024.08.023_bib38","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1001\/jamaophthalmol.2024.1822","article-title":"Melatonin and risk of age-related macular degeneration","volume":"142","author":"Jeong","year":"2024","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"10.1016\/j.ophtha.2024.08.023_bib39","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41591-023-02672-2","article-title":"Association of semaglutide with risk of suicidal ideation in a real-world cohort","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.ophtha.2024.08.023_bib40","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2021.4182","article-title":"Racial, ethnic, and socioeconomic inequities in glucagon-like peptide-1 receptor agonist use among patients with diabetes in the US","volume":"2","author":"Eberly","year":"2021","journal-title":"JAMA Health Forum"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642024005153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642024005153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T13:51:35Z","timestamp":1740059495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642024005153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0161642024005153"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2024.08.023","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Effects of Glucagon-like Peptide 1 Receptor Agonists and Metformin on Glaucoma Risk in Patients with Type 2 Diabetes","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2024.08.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}